TreatmentAdjuvant ribociclib adds a six-year survival benefit in high-risk diseaseThe six-year follow-up of the NATALEE trial confirms that adding ribociclib to endocrine therapy improves overall survival in high-risk HR+/HER2- early breast cancer, with a modest absolute gain....oncomamaAnn OncolNovember 5, 2026
Breast UnitsPrevention & ScreeningTranslating absolute breast cancer risk into how often to screenoncomamaJ Natl Cancer InstNovember 5, 2026
Breast UnitsDiagnosisPET/MRI changes the treatment plan in almost one third of early breast cancersoncomamaEur J CancerNovember 4, 2026
MeetingsTreatmentMiami reviews the controversies in breast cancer treatment in MarchoncomamaMBCC 2027November 4, 2026
DiagnosisPrevention & ScreeningMammography beyond five years does not prevent advanced tumours in older survivorsoncomamaJAMA Intern MedNovember 4, 2026
